Cargando…

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis. As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Amin, Zeng, Peiting, Li, Yinguang, Lu, Wenhua, Lai, Yaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606661/
https://www.ncbi.nlm.nih.gov/pubmed/34820336
http://dx.doi.org/10.3389/fonc.2021.782065
_version_ 1784602380192448512
author Huang, Amin
Zeng, Peiting
Li, Yinguang
Lu, Wenhua
Lai, Yaoming
author_facet Huang, Amin
Zeng, Peiting
Li, Yinguang
Lu, Wenhua
Lai, Yaoming
author_sort Huang, Amin
collection PubMed
description Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis. As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC), with its preclinical and clinical activity demonstrated in the treatment of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutant AML. Even though it shows a rosy future in the AML treatment, the short response duration remains a vital problem that leads to treatment failure. Rapid onset of drug resistance is still a thorny problem that we cannot overlook. Although the mechanisms of drug resistance have been studied extensively in the past years, there is still no consensus on the exact reason for resistance and without effective therapeutic regimens established clinically. My previous work reported that sorafenib-resistant FLT3-ITD mutant AML cells displayed mitochondria dysfunction, which rendered cells depending on glycolysis for energy supply. In my present one, we further illustrated that losing the target protein FLT3 and the continuously activated PI3K/Akt signaling pathway may be the reason for drug resistance, with sustained activation of PI3K/AKT signaling responsible for the highly glycolytic activity and adenosine triphosphate (ATP) generation. PI3K inhibitor, LY294002, can block PI3K/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. This finding would pave the way to remedy the FLT3-ITD mutant AML patients who failed with FLT3 targeted therapy.
format Online
Article
Text
id pubmed-8606661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86066612021-11-23 LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway Huang, Amin Zeng, Peiting Li, Yinguang Lu, Wenhua Lai, Yaoming Front Oncol Oncology Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis. As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC), with its preclinical and clinical activity demonstrated in the treatment of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutant AML. Even though it shows a rosy future in the AML treatment, the short response duration remains a vital problem that leads to treatment failure. Rapid onset of drug resistance is still a thorny problem that we cannot overlook. Although the mechanisms of drug resistance have been studied extensively in the past years, there is still no consensus on the exact reason for resistance and without effective therapeutic regimens established clinically. My previous work reported that sorafenib-resistant FLT3-ITD mutant AML cells displayed mitochondria dysfunction, which rendered cells depending on glycolysis for energy supply. In my present one, we further illustrated that losing the target protein FLT3 and the continuously activated PI3K/Akt signaling pathway may be the reason for drug resistance, with sustained activation of PI3K/AKT signaling responsible for the highly glycolytic activity and adenosine triphosphate (ATP) generation. PI3K inhibitor, LY294002, can block PI3K/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. This finding would pave the way to remedy the FLT3-ITD mutant AML patients who failed with FLT3 targeted therapy. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606661/ /pubmed/34820336 http://dx.doi.org/10.3389/fonc.2021.782065 Text en Copyright © 2021 Huang, Zeng, Li, Lu and Lai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Amin
Zeng, Peiting
Li, Yinguang
Lu, Wenhua
Lai, Yaoming
LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title_full LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title_fullStr LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title_full_unstemmed LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title_short LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
title_sort ly294002 is a promising inhibitor to overcome sorafenib resistance in flt3-itd mutant aml cells by interfering with pi3k/akt signaling pathway
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606661/
https://www.ncbi.nlm.nih.gov/pubmed/34820336
http://dx.doi.org/10.3389/fonc.2021.782065
work_keys_str_mv AT huangamin ly294002isapromisinginhibitortoovercomesorafenibresistanceinflt3itdmutantamlcellsbyinterferingwithpi3kaktsignalingpathway
AT zengpeiting ly294002isapromisinginhibitortoovercomesorafenibresistanceinflt3itdmutantamlcellsbyinterferingwithpi3kaktsignalingpathway
AT liyinguang ly294002isapromisinginhibitortoovercomesorafenibresistanceinflt3itdmutantamlcellsbyinterferingwithpi3kaktsignalingpathway
AT luwenhua ly294002isapromisinginhibitortoovercomesorafenibresistanceinflt3itdmutantamlcellsbyinterferingwithpi3kaktsignalingpathway
AT laiyaoming ly294002isapromisinginhibitortoovercomesorafenibresistanceinflt3itdmutantamlcellsbyinterferingwithpi3kaktsignalingpathway